23-Apr-2024
Barclays Reaffirms Their Buy Rating on McKesson (MCK)
TipRanks (Wed, 24-Apr 4:46 AM ET)
Buy Rating Reaffirmed for McKesson Amid Strong Growth Prospects and OptumRx Contract Win
TipRanks (Wed, 24-Apr 2:26 AM ET)
Goldman’s buybacks basket: Buyback growth will be 13% in 2024
Seeking Alpha News (Mon, 22-Apr 1:23 PM ET)
Buy Rating Affirmed: McKesson’s Strategic Growth Bolstered by OptumRx Contract Win
TipRanks (Mon, 22-Apr 12:15 PM ET)
McKesson Corporation Announces Fourth Quarter Fiscal 2024 Earnings Release Date
Business Wire (Wed, 27-Mar 4:10 PM ET)
McKesson Corporation Reports Fiscal 2024 Third Quarter Results and Raises Full Year Guidance
Business Wire (Wed, 7-Feb 4:10 PM ET)
McKesson Corporation Declares Quarterly Dividend
Business Wire (Thu, 1-Feb 8:00 AM ET)
McKesson Corp is one of three leading pharmaceutical wholesalers in the U.S. engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the U.S. pharmaceutical wholesale industry. Outside the U.S. market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Mckesson trades on the NYSE stock market under the symbol MCK.
As of April 23, 2024, MCK stock price climbed to $532.00 with 359,054 million shares trading.
MCK has a beta of -0.06, meaning it tends to be less sensitive to market movements. MCK has a correlation of 0.00 to the broad based SPY ETF.
MCK has a market cap of $84.16 billion. This is considered a Large Cap stock.
Last quarter Mckesson reported $81 billion in Revenue and $7.74 earnings per share. This beat revenue expectation by $3 billion and exceeded earnings estimates by $.69.
In the last 3 years, MCK stock traded as high as $543.00 and as low as $180.42.
The top ETF exchange traded funds that MCK belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.
MCK has outperformed the market in the last year with a price return of +48.5% while the SPY ETF gained +24.3%. MCK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.3% and 0.0%, respectively, while the SPY returned +4.9% and -2.5%, respectively.
MCK support price is $521.13 and resistance is $533.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCK stock will trade within this expected range on the day.